Long acting formulation of biopharmaceutical
US8247493B2 · kind B2 · utility
0Cited by
0References
2Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Apr 13, 2009 |
| Grant date | Aug 21, 2012 |
| Priority date | — |
| Expiry date | Nov 13, 2030 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC08L2203/02
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention relates to a long-acting formulation of biopharmaceutical, more specifically an aptamer therapeutics. A branched PEGylated aptamer or a hyaluronic acid (HA) derivative of which degradation in vivo is regulated is linked by the bioconjugation with biopharmaceutical to produce the long-action formulation.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.